Company Description

CavGene's lead product is a first-in-class Adeno-associated virus delivered RNA interference (RNAi) therapeutic targeting a voltage-gated L-type calcium channel known as Cav1.3, in a brain region known as the striatum for the treatment of levodopa-induced dyskinesias (LID), a significant side-effect associated with the standard of treatment for Parkinson’s disease.